Skip to main content

Selecky Christobel's Form 4 filing

ImmunityBio, Inc. (IBRX) · filed Jan 21, 2026

Accession no.
0001849739-26-000002
Filed
Jan 21, 2026
Trade date
Jan 16-20, 2026
Filing delay
5 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $437.8K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Selecky ChristobelCIK 0001849739Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 16, 2026Common StockMOption exerciseAcquired+50,000$2.98+$149,00050,000Direct
Jan 16, 2026Common StockSSaleDisposed−50,000$5.00−$250,0000Direct
Jan 20, 2026Common StockMOption exerciseAcquired+25,000$2.98+$74,50025,000Direct
Jan 20, 2026Common StockSSaleDisposed−25,000$7.51F2−$187,7500Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 16, 2026Common StockMOption exerciseDisposed−50,000$0.00$0117,937Direct
Jan 20, 2026Common StockMOption exerciseDisposed−25,000$0.00$092,937Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.50 to $7.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit 24 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)